Unusual Adverse Choroidal Reaction to Intravitreal Bevacizumab in Aggressive Posterior Retinopathy of Prematurity: The Indian Twin Cities ROP Screening (ITCROPS) Data Base Report Number 7

Abstract Purpose: To describe a case of choroidal ischemia in a neonate after single, bilateral, intravitreal bevacizumab (IVB) injection for severe zone 1 aggressive posterior retinopathy of prematurity (AP-ROP). Methods: A six-week-old baby, born at a gestation age of 28 weeks and birth weight of 1.08 kg, presented at a postconceptional age of 34 weeks for ROP screening. On examination, both eyes revealed engorged iris new vessels with poorly dilating pupils. Retinal examination showed media haze, severe zone 1 APROP with confluent new vessels, severe plus disease, and early vitreous condensation at the edge of new vessels for 12 clock hours. The child was treated bilaterally, with single IVB injection before laser. After 16 hours, hypotony and exudative retinal detachment with patches of choroidal whitening suggestive of choroidal ischemia were seen. Results: The child was treated with topical steroids and cycloplegic drops and exudative retinal detachment resolved on the tenth day. Initial resolution of new vessels showed recurrence after two weeks and was treated with laser photocoagulation. Stable retinopathy status was noted up to six months follow-up. Conclusion: Choroidal ischemia secondary to a single IVB injection for the treatment of AP-ROP could be an unusual complication which raises the concern of its use as a monotherapy in neonates.

[1]  A. Tsao Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Non–Small-Cell Lung Cancer: The ECOG 3598 Study , 2012 .

[2]  Y. Le,et al.  Presence of RPE-produced VEGF in a timely manner is critical to choroidal vascular development. , 2012, Advances in experimental medicine and biology.

[3]  R. Azad Use of intravitreal anti-VEGF: Retinopathy of prematurity surgeons’ in Hamlet's dilemma? , 2011, Indian journal of ophthalmology.

[4]  S. Jalali,et al.  Outcomes of a protocol-based management for zone 1 retinopathy of prematurity: the Indian Twin Cities ROP Screening Program report number 2. , 2011, American journal of ophthalmology.

[5]  Alice Z Chuang,et al.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. , 2011, The New England journal of medicine.

[6]  L. Gopal,et al.  Technical aspects of laser treatment for acute retinopathy of prematurity under topical anesthesia , 2010, Indian journal of ophthalmology.

[7]  L. Atchaneeyasakul,et al.  Choroidal ruptures after adjuvant intravitreal injection of bevacizumab for aggressive posterior retinopathy of prematurity , 2010, Journal of Perinatology.

[8]  A. Negi,et al.  Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.

[9]  J. Kim,et al.  Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurity , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[10]  W. Tasman,et al.  Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. , 2004, Archives of ophthalmology.

[11]  A. Fielder,et al.  Preliminary results of treatment of eyes with high-risk prethreshold retinopathy of prematurity in the early treatment for retinopathy of prematurity randomized trial. , 2003, Archives of ophthalmology.